6:31AM Questcor Pharma to initiate pilot commercialization effort in pulmonology for symptomatic sarcoidosis (QCOR) 47.20 : Co announced its intent to initiate a pilot commercialization effort for H.P. Acthar Gel (repository corticotropin injection) for the treatment of respiratory manifestations of symptomatic sarcoidosis, a potentially serious, difficult-to-treat disorder already included on the FDA-approved package insert for Acthar. The pilot effort will focus on pulmonologists. The co is also evaluating several potential clinical studies that have been recently proposed by key opinion leaders in the sarcoidosis field.
Rheumatologists are also treaters of sarcoidosis--since it is yet another of those autoimmune inflammatory disorders where the first line of treatment is corticosteroids. Disorder is manageable for most patients, but it can get out of control and when combined with SLE or some other autoimmune dysfunction, it can be disabling.
Quick primer for all interested parties.
Rheumatology--autoimmune specialist--almost synonomous these days with immunology.
Looks like the rheumatology sales force is starting to fulfill its potential--very, very good news.
Oh...and shorts...might consider covering before Q2...just a thought.